HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
Jan 2012 - :1097-0142 [PMID:22252842]
[Sharma A] [Koldovsky U] [Xu S] [Mick R] [Roses R] [Fitzpatrick E] [Weinstein S] [Nisenbaum H] [Levine BL] [Fox K] [Zhang P] [Koski G] [Czerniecki BJ]

A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer.
Dec 2011 - :1537-4513 [PMID:22130160]
[Koski GK] [Koldovsky U] [Xu S] [Mick R] [Sharma A] [Fitzpatrick E] [Weinstein S] [Nisenbaum H] [Levine BL] [Fox K] [Zhang P] [Czerniecki BJ]

Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission.
Oct 2011 - :1432-0851 [PMID:22021066]
[Chu CS] [Boyer J] [Schullery DS] [Gimotty PA] [Gamerman V] [Bender J] [Levine BL] [Coukos G] [Rubin SC] [Morgan MA] [Vonderheide RH] [June CH]

Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.
Feb 2007 - Cancer Res.; 67(4):0008-5472 [PMID:17293384]
[Czerniecki BJ] [Koski GK] [Koldovsky U] [Xu S] [Cohen PA] [Mick R] [Nisenbaum H] [Pasha T] [Xu M] [Fox KR] [Weinstein S] [Orel SG] [Vonderheide R] [Coukos G] [DeMichele A] [Araujo L] [Spitz FR] [Rosen M] [Levine BL] [June C] [Zhang PJ]

TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients.
Apr 2003 - Clin. Cancer Res.; 9(4):1078-0432 [PMID:12684428]
[Schlienger K] [Chu CS] [Woo EY] [Rivers PM] [Toll AJ] [Hudson B] [Maus MV] [Riley JL] [Choi Y] [Coukos G] [Kaiser LR] [Rubin SC] [Levine BL] [Carroll RG] [June CH]